UNSPSC 51411611: Bamethan sulfate

This classification denotes a beta-adrenergic agonist with the molecular formula 2C12H19NO2.H2O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier W2L3E1W827, chemically known as benzyl alcohol, alpha-((butylamino)methyl)-p-hydroxy-, sulfate (2:1) (salt) but more generally known as bamethan sulfate, which bears US NIH Compound Identifier 21955. European Medicines Agency schedules Bamethan sulfate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00660MIG.

Most nations, for tariff and trade purposes, schedule bamethan sulfate under HS 29225000 and SITC 51467. As of Q4 2014, BAMETHAN SULFATE remains US FDA's Preferred Term for this commodity. Bamethan sulfate bears US NLM identifiers UMLS ID C0350190 and NCI Concept Code C76117. SMILES: CCCCNCC(C1CCC(CC1)O)O.CCCCNCC(C1CCC(CC1)O)O.OS(=O)(=O)O.

UNSPSC 51411611 Bamethan sulfate is a Commodity code that nominally identifies a specific pharmaceutical active ingredient, but state and local procurement activity under this code demonstrates that government agencies are buying emergency medical medications and generic pharmaceuticals through multiple distribution and sourcing models rather than seeking bamethan sulfate specifically. The City of Tampa is procuring Advanced Life Support Medications including labetalol, epinephrine, adenosine, and diltiazem for fire rescue operations; the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) is establishing statewide and multi-state contracts for generic multi-source pharmaceuticals and over-the-counter products; and the Texas Health and Human Services Commission is exploring direct-to-manufacturer prescription fulfillment models to optimize pharmacy benefit administration. The issuing bodies span municipal fire and rescue departments, state health and human services agencies, and cooperative purchasing alliances operating across multiple jurisdictions, reflecting a mix of emergency-response procurement and broader public health supply chains.

Recent activity concentrates in Texas, Minnesota (with multi-state coverage including Oregon), and Florida. The Tampa Fire Rescue IFB (Solicitation 26P00188, due April 8, 2026, estimated value $40,000) seeks four specific emergency medications with firm pricing and delivery within ten days, subject to a 5 percent Small Local Business Enterprise bid discount. MMCAP's RFP (Solicitation S1070000015802, due March 26, 2026) establishes multi-award contracts for generic pharmaceuticals and OTC products effective July 1, 2026, requiring vendors to supply through three authorized wholesalers and meet cGMP and DSCSA compliance, with price competitiveness weighted at 75 percent of evaluation. Texas HHS's RFI (HHS0017013, posted April 3, 2026) is exploratory, seeking vendor capabilities for direct manufacturer contracting outside traditional pharmacy benefit manager and group purchasing organization channels. The code shows active state and local pharmaceutical procurement across emergency response, generic multi-source purchasing, and innovative dispensing models, with repeat cooperative purchasing activity and emphasis on pricing flexibility and regulatory compliance.